Jun 25, 2019 / 01:20PM GMT
Guyn Kim - BMO Capital Markets Equity Research - Analyst
All right. Good morning. My name is Do Kim. I'm one of the biotech analysts at BMO. Happy to have with us Brett Monia, COO of Ionis.
Questions and Answers:
Guyn Kim - BMO Capital Markets Equity Research - AnalystBrett, just to start off, as we recognize the 30 years that Ionis has been around, could you reflect on what the company has achieved in that time, where you are today and what we could expect as you transition to CEO?
Brett P. Monia - Ionis Pharmaceuticals, Inc. - Founder, COO, Senior VP of Translational Medicine & Director
Sure thing, Do, and happy to -- and good morning, everybody. I'm glad to be here. Thanks for the invitation to talk a little bit about Ionis and where we're at today.
So yes, indeed, this is our 30th-year anniversary, and there's a lot of celebrating going on right now in San Diego because we're very proud of what we've accomplished over the last 30 years. I think at the high level, Do, what we've done was
Trustpilot
